TNF-α and endotoxin serum levels in cancer patients undergoing intraperitoneal hyperthermic perfusion

References

• Barlogie B., Corry P. M., Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Research 1980; 40: 1165–1168
   PubMed Web of Science ®Google Scholar
• Beutler B. A., Milsark I. W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. Journal of Immunology 1985; 135: 3972–3977
   PubMed Web of Science ®Google Scholar
• Camussi G., Bussolini F., Salvidio G., Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. Journal of Experimental Medicine 1987; 166: 1390–1404
   PubMed Web of Science ®Google Scholar
• Cannon J. G., Tompkins R. G., Gelfand J. A. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. Journal of Infectious Disease 1990; 161: 79–84
   PubMed Web of Science ®Google Scholar
• Chapman P. B., Lester T. J., Casper E. S. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. Journal of Clinical Oncology 1987; 5: 1942–1951
   PubMed Web of Science ®Google Scholar
• Creaven P. J., Plager J. E., Dupere S. Phase 1 clinical trial of recombinant human tumor necrosis factor. Cancer Chemotherapy and Pharmacology 1987; 20: 137–144
   PubMed Web of Science ®Google Scholar
• Damas P., Reuter A., Gysen P., Demonty J., Lamy M., Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Critical Care Medicine 1989; 17: 975–978
   PubMed Web of Science ®Google Scholar
• Dinarello C. A., Neta R. An overview on interleukin-1 as a therapeutic agent. Biotherapy 1990; 1: 245–254
   Google Scholar
• Dubois M. F., Ferrieux C., Lebon P. Synergistic cytotoxic effects of recombinant human tumor necrosis factor, interferons, and heat stress. Cancer Research 1989; 49: 5618–5622
   PubMedGoogle Scholar
• Fong Y., Moldawer L. L., Shires G. T., Lowry S. F. The biological characteristics of cytokines and their implication in surgical injury. Surgery, Gynecology and Obstetrics 1990; 170: 363–378
   PubMedGoogle Scholar
• Fujimoto S., Shrestha R. D., Kokubun M., Kobayashi K., Kiuchi S., Takahashi M., Konno C., Ohta M., Koike S., Kitsukawa Y., Mizutani M., Okui K. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 1989; 64: 154–161
   PubMedGoogle Scholar
• Gathiram P., Gaffin S. L., Brock-Utne J. G., Wells M. T. Time course of endotoxemia and cardiovascular changes in heat-stressed primates. Aviation, Space, and Environmental Medicine 1987; 58: 1071–1074
   PubMedGoogle Scholar
• Graber C. D., Reinhold R. B., Breman J. G., Harley R. A., Hennigar G. R. Fatal heat stroke. JAMA 1971; 216: 1195–1196
   PubMed Web of Science ®Google Scholar
• Hart P. H., Vitti G. F., Burgess D. R., Whitt G. A., Piccoli D. S., Hamilton J. A. Potential antiinflammatory effects of IL-4: suppression of human monocyte TNF α, IL-1 and PGE2. Proceeding of the National Academy of Sciences of USA 1989; 86: 3803–3807
   PubMed Web of Science ®Google Scholar
• Jäättelä M., Wissing D. Heat-shock proteins protect cells from monocyte cytotoxicity: Possible mechanism of self-protection. Journal of Experimental Medicine 1993; 177: 231–236
   PubMed Web of Science ®Google Scholar
• Maderazo E. G., Breaux S. P., Wonick C. L. Protective effects of ibuprofen and methylprednisolone on chemotactic factor-induced transcutaneus hypoxia. Journal of Pharmacology and Experimental Therapeutics 1986; 238: 453
   PubMedGoogle Scholar
• Marshall J., Sweeney D. Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Archives of Surgery 1990; 125: 17–23
   PubMedGoogle Scholar
• Mathison J. C., Wolfson E., Ulevitch R. J. Participation of tumor necrosis factor in the mediation of Gram negative bacterial lipopolysaccharide-induced injury in rabbits. Journal of Clinical Investigation 1988; 81: 1925–1937
   PubMed Web of Science ®Google Scholar
• Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. New England Journal of Medicine 1988; 318: 1481–1486
   PubMed Web of Science ®Google Scholar
• Michie H. R., Wilmore D. W. Sepsis and tumor necrosis factor-Bedfellows that cannot be ignored. Annals of Surgery 1990; 212: 653–654
   PubMedGoogle Scholar
• Shapiro L., Gelfand J. A. Cytokines and sepsis: pathophysiology and therapy. New Horizons 1993; 1: 13–22
   PubMedGoogle Scholar
• Shigleton W. W., Parker R. T., Mahaley S. Abdominal perfusion for cancer chemotherapy with hypothermia and hyperthermia. Surgery 1961; 50: 260–265
   Google Scholar
• Spratt J. S., Adcock R. A., Muskovin M., Sherrill R., McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Research 1980; 40: 256–260
   PubMed Web of Science ®Google Scholar
• Springgs D. R., Herman M. L., Michie H. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase 1 and pharmacologic study. Journal of the National Cancer Institute 1988; 80: 1039–1044
   PubMedGoogle Scholar
• Sone S., Yanagawa H., Nishioka Y., Orino E., Bhaskaran G., Nii A., Mizuno K., Heike Y., Ogushi F., Ogura T. Interleukin-4 as a potent down-regulator for human alveolar macrophages capable of producing tumor necrosis factor-α and interleukin-1. European Respiratory Journal 1992; 5: 174–181
   PubMed Web of Science ®Google Scholar
• Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Zentella A., Albert J. D., Shires G. T., Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470–474
   PubMed Web of Science ®Google Scholar
• Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–664
   PubMed Web of Science ®Google Scholar
• Valone F. H., Epstein L. B. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. Journal of Immunology 1988; 141: 3945–3950
   PubMed Web of Science ®Google Scholar
• Venezio F. R., Di Vincenzo C., Pearlman F., Phair J. P. Effects of the new nonsteroidal anti-inflammatory agents, ibuprofen, fenoprofen, and sulindac, on neutrophil adherence. Journal of Infectious Disease 1985; 152: 690–694
   PubMedGoogle Scholar
• Wagge A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clinical Immunology and Immunopathology 1987; 45: 348–355
   PubMedGoogle Scholar